CYP2C19 and attention deficit-hyperactivity disorder: In individuals with Autism Spectrum Disorder (ASD), CYP2C19 ultrarapid metabolisers were associated with decreased tolerance [19], while advances in population pharmacokinetics of Atomoxetine in children and adolescents with attention deficit hyperactivity disorder (ADHD) may help to guide individualised prescribing [20].